Details for New Drug Application (NDA): 209569
✉ Email this page to a colleague
The generic ingredient in TISSUEBLUE is brilliant blue g. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the brilliant blue g profile page.
Summary for 209569
| Tradename: | TISSUEBLUE |
| Applicant: | Dutch Ophthalmic |
| Ingredient: | brilliant blue g |
| Patents: | 0 |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for 209569
Generic Entry Date for 209569*:
Constraining patent/regulatory exclusivity:
INDICATED TO SELECTIVELY STAIN THE INTERNAL LIMITING MEMBRANE (ILM) Dosage:
SOLUTION;OPHTHALMIC |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for NDA: 209569
| Mechanism of Action | Dyes |
Suppliers and Packaging for NDA: 209569
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| TISSUEBLUE | brilliant blue g | SOLUTION;OPHTHALMIC | 209569 | NDA | D.O.R.C. Dutch Ophthalmic Research Center (International) B.V. | 68803-722 | 68803-722-05 | 10 POUCH in 1 CARTON (68803-722-05) / 1 SYRINGE, GLASS in 1 POUCH / .5 mL in 1 SYRINGE, GLASS |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;OPHTHALMIC | Strength | 0.025% | ||||
| Approval Date: | Dec 20, 2019 | TE: | RLD: | Yes | |||||
| Regulatory Exclusivity Expiration: | Dec 20, 2026 | ||||||||
| Regulatory Exclusivity Use: | INDICATED TO SELECTIVELY STAIN THE INTERNAL LIMITING MEMBRANE (ILM) | ||||||||
Complete Access Available with Subscription
